{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:31:47Z","timestamp":1789939907934,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T00:00:00Z","timestamp":1354924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00270-012-0532-8","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T01:42:12Z","timestamp":1354930932000},"page":"1039-1046","source":"Crossref","is-referenced-by-count":30,"title":["Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience"],"prefix":"10.1007","volume":"36","author":[{"given":"Sylvain","family":"Favelier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Boulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Cercueil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Cherblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Chauffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Kraus\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,8]]},"reference":[{"key":"532_CR1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.cgh.2010.07.018","volume":"8","author":"B Guiu","year":"2010","unstructured":"Guiu B, Minello A, Cottet V et al (2010) A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 8:986\u2013991","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9664","key":"532_CR2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(09)60381-0","volume":"373","author":"J Bruix","year":"2009","unstructured":"Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373(9664):614\u2013616","journal-title":"Lancet"},{"key":"532_CR3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"EASL\u2013EORTC","year":"2012","unstructured":"EASL\u2013EORTC (2012) EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908\u2013943","journal-title":"J Hepatol"},{"key":"532_CR4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429\u2013442","journal-title":"Hepatology"},{"key":"532_CR5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","volume":"30","author":"L Marelli","year":"2007","unstructured":"Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? a systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6\u201325","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9319","key":"532_CR6","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734\u20131739","journal-title":"Lancet"},{"key":"532_CR7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s00270-010-9794-1","volume":"33","author":"KH Lee","year":"2010","unstructured":"Lee KH, Liapi EA, Cornell C et al (2010) Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 33:576\u2013582","journal-title":"Cardiovasc Intervent Radiol"},{"key":"532_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jvir.2009.10.026","volume":"21","author":"J Namur","year":"2010","unstructured":"Namur J, Wassef M, Millot JM et al (2010) Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J Vasc Interv Radiol 21:259\u2013267","journal-title":"J Vasc Interv Radiol"},{"key":"532_CR9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","volume":"33","author":"K Malagari","year":"2010","unstructured":"Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541\u2013551","journal-title":"Cardiovasc Intervent Radiol"},{"key":"532_CR10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jvir.2009.10.038","volume":"21","author":"A Nicolini","year":"2010","unstructured":"Nicolini A, Martinetti L, Crespi S et al (2010) Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21:327\u2013332","journal-title":"J Vasc Interv Radiol"},{"key":"532_CR11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/CAD.0b013e328346a0c5","volume":"22","author":"M Boulin","year":"2011","unstructured":"Boulin M, Guiu S, Chauffert B et al (2011) Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs 22:741\u2013748","journal-title":"Anticancer Drugs"},{"key":"532_CR12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1470-2045(04)01508-6","volume":"5","author":"A Burroughs","year":"2004","unstructured":"Burroughs A, Hochhauser D, Meyer T (2004) Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5:409\u2013418","journal-title":"Lancet Oncol"},{"key":"532_CR13","first-page":"559","volume":"15","author":"M Minemura","year":"1999","unstructured":"Minemura M, Tanimura H, Tabor E (1999) Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 15:559\u2013563","journal-title":"Int J Oncol"},{"key":"532_CR14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/86.9.700","volume":"86","author":"JG Park","year":"1994","unstructured":"Park JG, Lee SK, Hong IG et al (1994) MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 86:700\u2013705","journal-title":"J Natl Cancer Inst"},{"key":"532_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF01737687","volume":"66","author":"M Goebel","year":"1993","unstructured":"Goebel M (1993) Oral idarubicin\u2014an anthracycline derivative with unique properties. Ann Hematol 66:33\u201343","journal-title":"Ann Hematol"},{"key":"532_CR16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208\u20131236","journal-title":"Hepatology"},{"key":"532_CR17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","volume":"56","author":"B Guiu","year":"2012","unstructured":"Guiu B, Deschamps F, Aho S et al (2012) Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs drug-eluting beads. J Hepatol 56:609\u2013617","journal-title":"J Hepatol"},{"key":"532_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"J Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41\u201352","journal-title":"Cardiovasc Intervent Radiol"},{"key":"532_CR19","doi-asserted-by":"crossref","first-page":"W562","DOI":"10.2214\/AJR.10.4379","volume":"197","author":"TJ Vogl","year":"2011","unstructured":"Vogl TJ, Lammer J, Lencioni R et al (2011) Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 197:W562\u2013W570","journal-title":"AJR Am J Roentgenol"},{"key":"532_CR20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1148\/radiol.10091473","volume":"255","author":"RJ Lewandowski","year":"2010","unstructured":"Lewandowski RJ, Mulcahy MF, Kulik LM et al (2010) Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 255:955\u2013965","journal-title":"Radiology"},{"issue":"2 suppl 6","key":"532_CR21","first-page":"S6-38","volume":"24","author":"S Kawai","year":"1997","unstructured":"Kawai S, Tani M, Okamura J et al (1997) Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 24(2 suppl 6):S6-38\u2013S36-45","journal-title":"Semin Oncol"},{"issue":"suppl","key":"532_CR22","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1007\/BF00686676","volume":"33","author":"S Watanabe","year":"1994","unstructured":"Watanabe S, Nishioka M, Ohta Y et al (1994) Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 33(suppl):S93\u2013S96","journal-title":"Cancer Chemother Pharmacol"},{"key":"532_CR23","first-page":"739","volume":"68","author":"M Broggini","year":"1984","unstructured":"Broggini M, Italia C, Colombo T et al (1984) Activity and distribution of IV and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 68:739\u2013747","journal-title":"Cancer Treat Rep"},{"key":"532_CR24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0145-2126(99)00041-7","volume":"23","author":"DJ Roovers","year":"1999","unstructured":"Roovers DJ, van Vliet M, Bloem AC, Lokhorst HM (1999) Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 23:539\u2013548","journal-title":"Leuk Res"},{"key":"532_CR25","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood.V79.12.3267.3267","volume":"79","author":"E Berman","year":"1992","unstructured":"Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267\u20133273","journal-title":"Blood"},{"key":"532_CR26","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1478-3231.2008.01889.x","volume":"28","author":"S Vander Borght","year":"2008","unstructured":"Vander Borght S, Komuta M, Libbrecht L et al (2008) Expression of multidrug resistance\u2013associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 28:1370\u20131380","journal-title":"Liver Int"},{"key":"532_CR27","unstructured":"Tumolo S, Toffoli G, Bearz A et al (2002) Oral idarubicin (IDA) for the treatment of hepatocellular carcinoma (HCC). Paper presented at 2002 ASCO annual meeting"},{"key":"532_CR28","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V77.8.1666.1666","volume":"77","author":"E Berman","year":"1991","unstructured":"Berman E, Heller G, Santorsa J et al (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666\u20131674","journal-title":"Blood"},{"key":"532_CR29","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jhep.2012.07.017","volume":"57","author":"MJ Song","year":"2012","unstructured":"Song MJ, Chun HJ, Song DS et al (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57:1244\u20131250","journal-title":"J Hepatol"},{"key":"532_CR30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00001813-200111000-00003","volume":"12","author":"P Favoulet","year":"2001","unstructured":"Favoulet P, Cercueil JP, Faure P et al (2001) Increased cytotoxicity and stability of lipiodol\u2013pirarubicin emulsion compared to classical doxorubicin\u2013lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs 12:801\u2013806","journal-title":"Anticancer Drugs"},{"key":"532_CR31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(91)90873-A","volume":"13","author":"PJ Johnson","year":"1991","unstructured":"Johnson PJ, Kalayci C, Dobbs N et al (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13:120\u2013127","journal-title":"J Hepatol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-012-0532-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00270-012-0532-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-012-0532-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T08:52:59Z","timestamp":1595062379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00270-012-0532-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1007\/s00270-012-0532-8","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,8]]}}}